PT-141 Research Evidence
The PT-141 evidence base: trials, journals, and what the data does not yet show.
Key Findings at a Glance
• PT-141 is the only FDA-approved peptide for sexual dysfunction, marketed as Vyleesi for treating hypoactive sexual desire disorder in premenopausal women. • PT-141 works through melanocortin-4 receptors in the brain rather than through vascular mechanisms, making it fundamentally different from PDE5 inhibitors like sildenafil. • PT-141 was originally discovered as a side effect during Melanotan II tanning research, when male subjects unexpectedly reported spontaneous erections during clinical trials. • Because PT-141 acts centrally on desire pathways rather than on blood flow, it is effective in populations where vascular-based treatments fail, including some forms of psychogenic dysfunction.
Sexual Function Research
Extensive clinical research on PT-141 for sexual dysfunction treatment has demonstrated significant improvements in sexual desire and arousal through central melanocortin receptor activation in the hypothalamus and limbic system. Phase 3 clinical trials involving over 1,200 premenopausal women with hypoactive sexual desire disorder (HSDD) showed statistically significant increases in satisfying sexual events and reductions in distress related to low sexual desire compared to placebo groups. Unlike phosphodiesterase type 5 (PDE5) inhibitors that work through vascular mechanisms, PT-141 operates through the central nervous system, making it effective for desire-related sexual dysfunction research rather than purely mechanical arousal issues. Studies have documented onset of effects within 30-60 minutes following subcutaneous administration, with effects lasting up to 24 hours in some research subjects. These findings have positioned PT-141 as a unique research compound for investigating neural pathways involved in female sexual dysfunction treatment, male erectile dysfunction research, and understanding the neurobiological basis of sexual motivation and arousal.
Central Nervous System Effects
Neuroimaging and behavioral studies indicate PT-141 produces significant central nervous system effects on motivation, reward processing, and emotional regulation through melanocortin receptor activation in limbic structures. Functional MRI research has shown increased activity in brain regions associated with sexual arousal and desire following PT-141 administration, including the anterior cingulate cortex and insula. Studies demonstrate the peptide's effects are mediated through descending neural pathways from the hypothalamus to the spinal cord, influencing both autonomic and somatic components of sexual response. Research has documented effects on dopaminergic neurotransmission, with PT-141 potentially modulating dopamine release in reward-related brain circuits. These CNS-mediated effects distinguish PT-141 from peripheral-acting sexual dysfunction treatments and have generated interest in its potential applications for research into depression-related sexual dysfunction, motivational disorders, and understanding the neuroscience of desire and reward processing.
PT-141 (Bremelanotide) and Melanocortin Receptor Signaling: MC4R Activation, Sex
PT-141 (bremelanotide; Vyleesi®) is a cyclic heptapeptide melanocortin receptor agonist that activates MC1R, MC3R, and MC4R receptors in the central nervous system and peripheral tissues. Unlike PDE5 inhibitors (sildenafil, tadalafil) that act on vascular smooth muscle, bremelanotide acts centrally in the medial preoptic area, paraventricular nucleus, and limbic circuits to increase sexual motivation and arousal independent of genital vascular physiology. FDA-approved in 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women, bremelanotide represents the first approved treatment acting through the CNS melanocortin pathway for sexual dysfunction.
Trials and reviews
- Kingsberg RECONNECT phase 3Obstet Gynecol2019
significant improvement in desire score (FSFI-D) + reduction in distress (FSDS-DAO) vs placebo over 24 wks · N=1247
- Wessells MT-II human ED studyInt J Impot Res2000
parent-molecule erection-onset RCT · 17/20 men with organic ED · N=20
References
- Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder · Kingsberg SA, et al. · 2019
- Kingsberg SA, et al. Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials. Obstet Gynecol. 2019;134(5):899-908. · Kingsberg SA, Clayton AH, Portman D, Williams LA, Krop J, Jordan R, Lucas J, Simon JA · 2019
- Safety Profile of Bremelanotide Across the Clinical Development Program. · Clayton AH, Kingsberg SA, Portman D et al. · 2022
- The neurobiology of bremelanotide for the treatment of hypoactive ... · Pfaus JG, Sadiq A, Spana C, Clayton AH · 2022
- Clayton AH, et al. Long-term safety and efficacy of bremelanotide for hypoactive sexual desire disorder. Obstet Gynecol. 2019;134(5):909-917. · Simon JA, Kingsberg SA, Portman D, Williams LA, Krop J, Jordan R, Lucas J, Clayton AH · 2019
- Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide. · Simon JA, Kingsberg SA, Portman D et al. · 2022
- [PDF] Vyleesi (bremelanotide) - accessdata.fda.gov
- Diamond LE, et al. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist. J Sex Med. 2006;3(4):628-38. · Diamond LE, Earle DC, Heiman JR, Rosen RC, Perelman MA, Harning R · 2006
- Safarinejad MR. Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study. J Urol. 2008;179(3):1066-71. · Safarinejad MR, Hosseini SY · 2008
- Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder. · Simon JA, Kingsberg SA, Portman D et al. · 2019
- Bremelanotide - LiverTox - NCBI Bookshelf - NIH
- Molinoff PB, et al. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Ann N Y Acad Sci. 2003;994:96-102. · Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY · 2003
- Bremelanotide: First Approval - PubMed · Dhillon S, Keam SJ · 2019